Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
ASND Stock Chart & Stats
$222.03
-$0.55(-0.40%)
At close: 4:00 PM EST
$222.03
-$0.55(-0.40%)
Day’s Range― - ―
52-Week Range$118.03 - $242.00
Previous CloseN/A
Volume129.18K
Average Volume (3M)621.53K
Market Cap
$13.57B
Enterprise Value$11.39B
Total Cash (Recent Filing)$539.09M
Total Debt (Recent Filing)$813.65M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding61,151,463
10 Day Avg. Volume634,124
30 Day Avg. Volume621,534
Financial Highlights & Ratios
PEG Ratio0.86
Price to Book (P/B)-72.81
Price to Sales (P/S)21.17
P/FCF Ratio-25.02
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue17.62
Enterprise Value/Gross Profit20.30
Enterprise Value/Ebitda-85.55
Forecast
1Y Price Target
$277.08Price Target Upside24.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DifferentiationClinical data indicate TransCon CNP, alone and combined with human growth hormone, sustained growth velocity and improved arm span and body proportionality, suggesting clear functional benefits that could set the therapy apart from competitors.
Commercial Expansion And Financial RunwayGrowing prescription uptake for Yorvipath in the United States, low current penetration in ex-US markets, and a substantial cash position support the capacity to expand commercial availability and pursue international launches.
Regulatory Pathway ClarityCompletion of an End-of-Phase-two meeting with the FDA and a planned pivotal Phase three trial comparing the combination to monotherapy create a defined clinical development plan that can reduce approval uncertainty.
Bears Say
Administration Complexity And Formulation TimelineThe current administration as two separate injections and the absence of a disclosed timeline for a single-injection coformulation may hinder adherence and make it harder to protect market share from off-label combinations.
Durability Concerns For Combination TherapyKey opinion leaders expressed that the growth hormone component may provide only a short-lived benefit, creating uncertainty about the long-term value of the CNP and hGH combination.
Oral Competitor ThreatAn emerging oral therapy that avoids injections could attract patients seeking convenience and pose a material competitive risk to an injectable TransCon CNP offering.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $118.03 and its highest was $242.00 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $13.57B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is May 27, 2026 which is in 104 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Feb 11, 2026. The company reported -$0.653 earnings per share for the quarter, missing the consensus estimate of -$0.227 by -$0.427.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 61,151,463 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$0.653 in its last earnings report, missing expectations of -$0.227. Following the earnings report the stock price went up 3.629%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Currently, no hedge funds are holding shares in ASND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$277.08 (24.79% Upside)
$277.08 (24.79% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 124.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.15%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ASND Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive and growth-focused: management reported strong commercial execution (notably Yorvipath and Skytrofa), meaningful pipeline and regulatory progress (including imminent PDUFA for TransCon CNP and compelling combination data), and a strengthened cash position with an ambitious operating cash flow outlook for 2026. Key headwinds include high operating expenses (which slightly exceeded 2025 revenue), a substantial noncash finance remeasurement loss, currency-driven revenue headwinds, and remaining access / penetration and competitive uncertainties. Taken together the positives around revenue momentum, pipeline advancement, partnerships, and a stronger financial base outweigh the near-term financial and market-access challenges.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$277.08
▲(24.79% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Madrigal Pharmaceuticals
―
United Therapeutics
―
BridgeBio Pharma
―
Ownership Overview
Currently, No data available
---